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Abstract
Background: Evidences show that around 20% of biosimilar or originator erythropoiesis-stimulating agents (ESAs)
users are hyporesponsive. Controversial post-marketing data exist on the predictors of ESA hyporesponsiveness. The
aim of this study was to identify predictors of ESA hyporesponsiveness in patients with chronic kidney disease
(CKD) or cancer in clinical practice.
Methods: During the years 2009–2015, a multi-center, population-based, cohort study was conducted using claims
databases of Treviso and Caserta Local Health Units (LHUs). All incident ESA users were characterized at baseline
and the differences between the baseline hemoglobin (Hb) value, that is the Hb registered within 30 days prior to
the first ESA dispensing (index date, ID) and each outcome Hb value (registered between 30 and 180 days after ID)
were calculated and defined as delta Hb (ΔHb). Incident ESA users were defined as hyporesponsive if, during
follow-up, they registered at least one ΔHb < 0 g/dL. Including all potential predictors of ESA hyporesponsiveness
and stratifying by indication for use, univariate and multivariate binary logistic regression models and Receiver
Operating Characteristic (ROC) curves were carried out.
Results: In general, 1080 incident ESA users (CKD: 57.0%; cancer: 43.0%) were identified. In CKD, predictors of ESA
hyporesponsiveness were C-reactive protein (OR = 1.2, 95% CI: 1.0–1.5; P-value = 0.060) and high levels of baseline
Hb (OR = 1.7, 95% CI: 1.2–2.2; P-value< 0,001), the latter being also predictor of ESA hyporesponsiveness in cancer
(OR = 1.7, 95% CI: 1.1–2.4; P-value = 0.007). Both in CKD and in cancer, the type of ESA, biosimilar or originator, was
not a predictor of ESA hyporesponsiveness. In CKD, concomitant use of iron preparations (OR = 0.3, 95% CI: 0.2–0.7;
P-value = 0.002) and of high dosage of angiotensin-converting enzyme inhibitors/angiotensin II-receptor blockers
(OR = 0.5, 95% CI: 0.3–0.9; P-value = 0.022) were protective factors against ESA hyporesponsiveness.
Conclusions: The study confirmed traditional potential predictors of hyporesponsiveness to ESA. The use of
biosimilar or originator ESA was not a predictor of hyporesponsiveness in an outpatient setting from two large
Italian areas. A better knowledge of the predictors of ESA response would allow a better anemia management to
improve patients’ quality of life.
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Introduction
Erythropoiesis-stimulating agents (ESAs) are biological
products, analogues of human erythropoietin, produced
by cell lines using the recombinant DNA technology.
ESAs are approved for the treatment of anaemia related to
chronic kidney disease (CKD) or chemotherapy-induced
in cancer patients. According to the Italian Medicines
Agency, ESAs are indicated when hemoglobin (Hb) levels
are lower than 11 g/dl in CKD patients and lower than 10
g/dl in cancer patients. In Italy, for both indications, hae-
moglobinemia has to range between 11 and 12 g/dl [1],
avoiding a rise in Hb values greater than 2 g/dl over a
four-week period.
Generally, the term “ESA hyporesponsive” refers to pa-
tients who need high doses of ESAs (25–100% higher
doses than what recommended) to increase and/or
maintain their Hb levels within the acceptable range [2].
More specifically, the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines define patients as ESA hy-
poresponsive if they do not experience an increase in Hb
levels within the first month of ESA treatment, using an
appropriate weight-based dosing (not graded) [3].
ESA hyporesponsiveness could be acute or chronic,
but, to date, there is neither consensus nor shared pos-
ition on the definition of the chronic condition in par-
ticular [3]. Based on the definition gave by Sibbel et al.,
“4 months of continuous ESA hyporesponsiveness [defined
considering both Hb concentrations and ESAs doses] can
be used to differentiate acute from chronic hyporespon-
siveness” [4].
A previously published population-based study, con-
ducted on Italian administrative healthcare databases,
evaluated the comparative effectiveness of both biosimi-
lar and originator ESAs in CKD and cancer patients.
Results highlighted that, in clinical practice, around
20% of ESA users were non-responders, defined as sub-
jects experiencing no variations or a reduction in Hb
levels within the first 3 months of ESA treatment. Fur-
thermore, no differences were observed between differ-
ent type of ESAs (i.e., biosimilars or originators), in
terms of ESA responsiveness [5].
In patients with conservative end-stage renal disease,
as well as in dialysis patients, ESA hyporesponsiveness
and Hb level variability may lead to cardiovascular com-
plications, increasing the risk of all-cause mortality, due
to the required higher doses of ESA [6–8].
In both CKD and cancer patients, several factors may
contribute to ESA hyporesponsiveness, such as iron defi-
ciency, inflammation and malnutrition status, while
chronic hyperparathyroidism may affect ESA response in
CKD patients, specifically [9, 10].
Debate is still on-going regarding the potential effects of
renin-angiotensin system inhibitors, such as angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II-
receptor antagonists (ARBs), on the development of an-
aemia in patients with renal disease [11].
This naturalistic population-based study was aimed at
identifying which factors could be associated to ESA hy-
poresponsiveness in anaemic patients with CKD or can-
cer, in the general population of two Italian Local Health
Units (LHUs).
Methods
Data source
A population-based, retrospective, cohort study was con-
ducted. As data source, claims databases of Treviso and
Caserta LHUs, covering a total population of more than
1.5 million people during the years 2009–2015 (data
were available till 2014 in Treviso LHU), were consid-
ered. Each prescription of ESA requires a specific thera-
peutic plan to be filled in by specialists, specifying the
exact drug name, number of dispensed packages, dosing
regimen and indication for use of the drug. These data
can be linked, through anonymized patient unique iden-
tifier, to other claims databases including information on
hospital discharge diagnoses, healthcare service payment
exemptions, drug dispensing, outpatient diagnostic tests,
results of laboratory tests (in Caserta LHU, these data
are available only for a random sample of around 15% of
the general population), etc. ICD-9-CM diagnosis codes
were used to identify hospital discharge diagnoses and
indications for use, while Anatomical Therapeutic
Chemical (ATC) classification system codes and Italian
marketing authorization (AIC) codes, which distinguish
reference products from biosimilars and other ESAs still
covered by patent, were used to identify drug dispensing.
Additional details about data source can be found
elsewhere [12].
Study population
All the residents in Treviso or Caserta LHUs catchment
areas in the years 2009–2015 were included in the study,
if they had at least 1 year of database history, at least one
ESA dispensing during the study period, with no ESAs
dispensing within the previous 6 months (i.e. incident
ESA users with 6-month washout period), at least one
Hb measurement within 1 month prior to the date of the
first ESA dispensing during the study period (i.e. Index
Date, ID), defined as baseline Hb value, and at least an-
other one between the 2nd and the 6th month after ID,
defined as outcome Hb value (Fig. 1).
The included subjects were observed from the month
prior to the ID to the first 6 months after the ID.
Patients were excluded in case they received at least
one blood transfusion from 1month prior to the ID to
the last observed outcome Hb value.
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Study drugs
All the available ESAs in Italy during the study period
were included in the study: epoetin alfa (ATC: B03XA01;
Eprex®, Abseamed®, Binocrit®), epoetin beta (ATC:
B03XA01; Neorecormon®), epoetin zeta (B03XA01; Reta-
crit®), darbepoetin alfa (ATC: B03XA02; Aranesp®), and
methoxypolyethyleneglycol-epoetin beta (ATC: B03XA03;
Mircera®). Binocrit®, Abseamed® and Retacrit® are biosimi-
lars of the reference product (Eprex®), while all other ESAs
are ESAs still covered by the patent.
Data analysis
ESA users were categorized as CKD or cancer patients,
according to indication for use recorded in the elec-
tronic therapeutic plan. In case of non-availability of
electronic therapeutic plans, an algorithm described else-
where was used to identify indication for use [12].
All incident ESA users were characterized at baseline, in
terms of demographics, clinical parameters (e.g. hemoglo-
binemia and hematic level of creatinine, albumin, ferritin,
folate, potassium, sideremia, parathyroid hormone, vita-
min B12, C-reactive protein (CRP), and transferrin satur-
ation), comorbidities including arrhythmia, ischemic heart
diseases, diabetes mellitus, heart failure and hypertension,
and concomitant use of iron preparations, folic acid, vita-
min B12 and ACE inhibitors/ARBs.
During follow-up, the distribution of mean Hb values
among incident ESA users was calculated.
The differences between the baseline Hb and each out-
come Hb value were calculated and defined as delta Hb
(ΔHb). Incident ESA users were classified as ESA hypo-
responsive if, during follow-up, they registered at least
one ΔHb < 0 g/dL. Only incident ESA users having a
baseline Hb value lower than 11 g/dL were included in
these analyses.
All analyses were stratified by indication for use.
Sensitivity analysis
Due to the lack of a shared position on the description
of ESA hyporesponsiveness, the definition of ESA hypo-
responsiveness was modified in the sensitivity analyses.
Incident ESA users with at least two consecutive out-
come Hb values ≥11 g/dL, were classified as ESA re-
sponders, irrespective of ΔHb. Elsewhere, they were
considered as ESA hyporesponsive patients.
Statistical analysis
Depending on the distribution for quantitative variables,
results were presented as mean ± standard deviation
(SD) or median with interquartile range (IQR), and by
absolute frequencies and percentages for categorical
variables.
Fig. 1 Flow-chart of study population. * no treatment within 6 months prior to Index Date (ID, i.e. date of ESA treatment start). ESA =
erythropoiesis-stimulating agents; Hb = hemoglobin; CKD = chronic kidney disease
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Univariate and multivariate binary logistic regression
models were performed to identify predictors of ESA hy-
poresponsiveness, stratifying by indication for use (CKD
and cancer). The dependent variable of the model was
the hyporesponsiveness to ESA treatment, that is at least
once ΔHb < 0 g/dL.
As covariates, all the potential predictors of ESA respon-
siveness identified from the database, including sex, age,
baseline Hb value, ESA dosage at ID, type of ESA dispensed
at ID (biosimilar, reference product or other ESAs still cov-
ered by patent), LHU, type of hospital discharge diagnosis
(categorized into cardiovascular, non-cardiovascular or
both cardiovascular and non-cardiovascular hospitaliza-
tions) within 1 year prior to ID, comorbidities (arrhythmia,
ischemic heart disease, diabetes mellitus, heart failure,
hypertension and dialysis, only for CKD patients), CKD
stage or type of tumor (i.e. solid malignant, non-solid ma-
lignant, both solid and non-solid malignant, or not classi-
fied), concomitant drug use (e.g. iron preparations, vitamin
B12, folic acid, high dosage of ACE inhibitor/ARBs) and la-
boratory values (e. g. hematic levels of creatinine, albumin,
ferritin, folate, potassium, sideremia, parathyroid hormone,
vitamin B12, C-reactive protein [CRP], transferrin satur-
ation, acidosis) were included in the model. By restricting
potential predictors to all those factors identified from the
database, reduce the likelihood of an overstatement.
In the multivariate model, we included all the covari-
ates, which were significantly associated to the outcome
at the univariate analysis. For each model, a Receiver
Operating Characteristic (ROC) curve was performed to
predict the discriminatory power of the variables in-
cluded in the model.
For each covariate tested as possible predictor of ESA hy-
poresponsiveness, the corresponding odds ratio (OR) were
reported along with 95% confidence interval (95% CI).
All statistical analyses were performed using SAS 9.3
(SAS Institute, Cary, NC) and SPSS/PC, Version 21
(SPSS Inc., Chicago, Illinois, USA). The significance level
for all statistical tests was set at p-value < 0.05.
Results
On a total population of 1,538,812 subjects registered in
Treviso and Caserta LHUs, 10,714 (0.7%) received at
least one ESA dispensing during the years 2009–2015; of
these, 1080 (10.1%) incident ESA users were included in
the study, based on the above-mentioned inclusion cri-
teria [CKD = 616 (57.0%); cancer = 464 (43.0%)] (Fig. 1).
As shown in Table 1, ESAs were in general more fre-
quently used by males among CKD patients, and by fe-
males among cancer patients. Regarding age distribution,
incident ESA users with CKD appeared to be on average
older (mean age ± SD: 72.6 ± 14.7) than patients with can-
cer (66.9 ± 12.2). Although most of ESA users started ESA
treatment having baseline Hb values within the range
recommended by the Italian guidelines (Hb < 10 g/dL in
cancer and Hb < 11 g/dL in CKD), 18.5% (N = 114) of
CKD patients and 10.3% (N = 48) of cancer patients
started ESA treatment with baseline Hb values ≥11 g/dL.
Around 45% of incident ESA users received a biosimilar
ESA at ID, irrespective of indication of use. In general,
CKD patients were more likely to be hospitalized than
cancer patients (66.2% vs. 56.2%), especially due to non-
cardiovascular diseases. As compared to cancer patients,
CKD patients were more likely to be affected by chronic
comorbidities, such as hypertension (93.2% vs. 66.8%) and
diabetes mellitus (41.9% of vs. 25.0%). Among ESA users
with CKD, 410 (66.5%) were affected by stage IV-V CKD
or were on dialysis. Instead, more than one third of cancer
patients were affected by solid malignant neoplasms, al-
though for most of cancer patients the type of tumor was
not known (N = 208; 44.8%). CKD patients were more
likely to be treated with iron preparations (CKD: 18.3%;
cancer: 8.4%) or anti-hypertensive drugs (ACE inhibitor or
ARBs) (CKD: 43.0%; cancer: 30.8%) than cancer patients.
Considering laboratory parameters, no differences were
found among cancer and CKD patients.
The target Hb value, as recommended by the Italian
Medicines Agency, was reached on average between 45
and 60 days after ID and was thereafter stable during fol-
low-up (Fig. 2).
Excluding incident ESA users with baseline Hb values
higher than recommended (i.e., ≥11 g/dL), we observed
that most of subjects included in the study cohort
reached, at least once, the target Hb values (11 ≤Hb
levels≤12 g/dL), according to recommendations from
Italian guidelines, despite 664 (61.5%) incident ESA users
reached Hb levels> 13.0 g/dL, at least once during fol-
low-up (Additional file 1).
Table 2 showed that, for each cohort, the proportion
of ESA hyporesponsive patients was similar using the
two approaches of ESA hyporesponsiveness. According
to the given definition of ESA hyporesponsiveness, the
multivariate binary logistic regression showed that the
type of dispensed ESA (biosimilar or originator) was not
a predictor of ESA response in CKD. Moreover, high
baseline Hb values (OR = 1.7, 95% CI: 1.2–2.2; P-value<
0.001) and CRP hematic levels (OR = 1.2, 95% CI: 1.0–
1.5; P-value = 0.060) were associated to ESA hyporespon-
siveness in CKD (Table 3), while high baseline Hb values
(OR = 1.7, 95% CI: 1.1–2.4; P-value = 0.007) and prior is-
chemic heart disease diagnosis (OR = 2.7, 95% CI: 0.9–
7.9; P-value = 0.072) were predictors of ESA hyporespon-
siveness in cancer patients (Table 4). On the contrary,
ESA hyporesponsiveness was decreased by concomitant
use of iron preparations (OR = 0.3, 95% CI: 0.2–0.7; P-
value = 0.002) and high dosage of ACE inhibitors/ARBs
(OR = 0.5, 95% CI: 0.3–0.9; P-value = 0.022) in CKD pa-
tients and by higher levels of albumin and potassium in
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Table 1 Characterization of incident ESA users at baseline
Cancer patients
N = 464
CKD patients
N = 616
Sex – N (%)
Males 217 (46.8) 356 (57.8)
Females 247 (53.2) 260 (42.2)
Age – yeara 66.9 ± 12.2 72.6 ± 14.7
Age category – N (%)
< 45 22 (4.7) 38 (6.1)
45–64 154 (33.2) 126 (20.5)
65–79 227 (48.9) 234 (38.0)
≥ 80 61 (13.2) 218 (35.4)
Baseline Hb - g/dLa 9.7 ± 1.1 10.1 ± 1.1
Baseline Hb ≥11 g/dL - N (%) 48 (10.3) 114 (18.5)
Days of ESA exposurea 101.8 ± 40.5 119.4 ± 41.0
ESA dosage during the follow-upa
IU 34,994.1 ± 9308.1 8564.6 ± 4835.4
Mcg 204.7 ± 132.1 49.9 ± 30.0
Catchment area –N (%)
Caserta 99 (21.3) 80 (13.0)
Treviso 365 (78.7) 536 (87.0)
Type of ESA – N (%)
Reference product 129 (27.8) 126 (20.5)
Biosimilar 209 (45.0) 284 (46.1)
Other ESAs covered by patent 126 (27.2) 206 (33.4)
Hospitalizations/PS visits – N(%)b
No 203 (43.8) 208 (33.8)
Cardiovascular hosp. 6 (1.3) 44 (7.1)
Non cardiovascular hosp. 244 (52.6) 283 (45.9)
Both cardiovascular and non-cardiovascular hosp. 11 (2.4) 81 (13.1)
Comorbidities – N (%)c
Arrhythmia 30 (6.5) 139 (22.6)
Ischemic heart disease 23 (5.0) 106 (17.2)
Diabetes mellitus 116 (25.0) 258 (41.9)
Heart failure 28 (6.0) 193 (31.3)
Hypertension 310 (66.8) 574 (93.2)
Dialysis – 90 (14.6)
Stage of CKD – N(%)
1 (GFR≥ 90) – 2 (0.3)
2 (90 > GFR≥ 60) – 11 (1.8)
3 (60 > GFR≥ 30) – 188 (30.5)
4 (30 > GFR≥ 15) – 230 (37.3)
5 and dialysis (GFR < 15 (or dialysis code)) – 180 (29.2)
Not classified 5 (0.8)
Type of tumor – N(%)
Benign 4 (0.9) –
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Table 1 Characterization of incident ESA users at baseline (Continued)
Cancer patients
N = 464
CKD patients
N = 616
Solid malignant 161 (34.7) –
Non solid malignant 72 (15.5) –
Both solid and non-solid malignant 19 (4.1) –
Non classified 208 (44.8) –
Concomitant drugs – N (%)d
Iron preparations 39 (8.4) 113 (18.3)
Vitamin B12 7 (1.5) 12 (1.9)
Folic acid 37 (8.0) 59 (9.6)
ACE Inhibitors/ARBs 143 (30.8) 265 (43.0)
Laboratory values
Albumin (g/dL; normal range: 3.5–5.5)a 3.6 ± 0.6 3.7 ± 0.6
Creatinine (mg/dL; normal range: M = 0.7–1.2; F = 0.6–1.2)e 0.9 (0.7–1.1) 2.5 (1.7–4.0)
Potassium (mEq/L; normal range: 3.6–5.0)a 4.4 ± 0.6 4.7 ± 0.7
Transferrin saturation (%)a 20.7 ± 14.3 22.3 ± 14.1
Sideremia (mcg/dL; normal range: M = 75–160; F = 60–150)e 56.0 (37.0–83.7) 50.0 (33.0–71.0)
Ferritin (mcg/L; normal range: M = 60–300; F = 30–150)e 278.4 (112.0–583.6) 150.6 (59.5–329.3)
Parathyroid hormone (pg/ml; normal range: 10–60)e 47.0 (27.0–79.0) 160.0 (85.0–300.3)
Vitamin B12 (ng/ml; normal range:300–900)
a 491.6 ± 224.3 506.9 ± 248.4
Folate (ng/ml; normal range: 2.7–17)e 6.0 (3.9–8.8) 5.2 (3.5–7.6)
CRP (mg/dL; normal value: < 0.5)e 0.9 (0.3–4.4) 0.9 (0.3–3.1)
CKD Chronic kidney disease, GFR Glomerular filtration rate, ACE angiotensin converting enzyme, ARBs Angiotensin II receptor antagonists, CRP C-reactive protein,
SD Standard deviation, IQR Interquartile range, IU International Unit, Mcg Microgram
aData are expressed as mean ± SD
bEvaluated within the year prior to ID
cEvaluated any time prior to ID
dEvaluated within 3 months prior to ID
eData are expressed as median and IQR
Fig. 2 Mean Hb variation during the follow-up, stratified by indication for use
Ylenia et al. BMC Nephrology          (2019) 20:359 Page 6 of 11
cancer patients, although not significantly (P-values>
0.005). The discriminatory power of the predictive re-
sponse of the variables included into the models was
good, as confirmed by the ROC curves (Figs. 3-4).
By modifying the ESA hyporesponsiveness definition
in the sensitivity analysis, high baseline Hb value was a
positive predictor of responsiveness both in CKD (OR =
0.7, 95% CI: 0.5–1.0; P-value = 0.053) and in cancer pa-
tients (OR = 0.5, 95% CI: 0.3–0.8; P-value = 0.003); that
is, patients with high baseline Hb values had more
chance to reach the target Hb values rather than patients
starting ESA treatment with low baseline Hb values
(Additional files 2, 3, 4, 5). In addition, concomitant use
of iron preparations and acidosis condition increased
ESA response in CKD patients, with a good predictive
power (AUC = 0.6969 ± 0.03; P-value< 0.001). Moreover,
males with CKD (OR = 0.5, 95% CI: 0.3–0.9; P-value:
0.011) seemed to be more responsive than females.
Discussion
Anaemia is a common complication in both cancer and
CKD patients and it could contribute to a poor prognosis.
ESA therapy represents the main treatment to increase
Hb levels in such groups of patients, leading to improve-
ment of quality of life and reducing the risk of cardio- and
cerebrovascular complications, as well as the requirement
of blood transfusions. However, ESA therapy must be
carefully handled due to the increased risk of stroke in
older patients having Hb levels above the target range. In-
deed, due to the occurrence of ESA resistance, the need
for higher doses of ESA may increase the risk of develop-
ing cardiovascular diseases and, ultimately, death [13].
Moreover, Minutolo et al. demonstrated that ESA hypore-
sponsiveness increased the risk of end stage renal disease
by 2.5-fold in CKD patients [14].
Our data confirmed that the inflammatory condition
and the iron intake affect ESA response. Inflammatory
cytokines may affect the development of anemia through
suppression of bone marrow erythropoiesis, suppression
of erythropoietin production, or interfering with the iron
status [15]. Several published studies demonstrated that
high levels of CRP in hemodialysis patients were associ-
ated with ESA hyporesponsiveness, leading to an in-
creased risk of death [16–18]. Although the prevalence
of ESA hyporesponsiveness in hemodialysis patients is
similar to that found in non-dialysis patients, limited
studies on the predictors of ESA hyporesponsiveness
have been conducted in the latter population [14].
Regarding the iron intake, our results highlighted that the
use of iron preparations was a predictive factor of ESA re-
sponse, whilst serum iron and ferritin were not independ-
ently associated to responsiveness to ESA treatment.
Although previous studies on hemodialysis patients demon-
strated that an altered iron status (in terms of low transfer-
rin saturation levels and/or low ferritin levels), is a common
factor inducing ESA hyporesponsiveness [19], there is no
general consensus regarding the role of iron status as a pre-
dictor of ESA response. A recent study examined the rela-
tionship between iron markers, such as transferrin
Table 2 Frequency of incident ESA hyporesponders
Cancer
N = 416 (%)
CKD
N = 502 (%)
Non responsiveness
ΔHb < 0 g/dLa 146 (35.1) 152 (30.3)
Hb < 11 g/dLb 135 (32.4) 147 (29.3)
Only incident ESA users having a baseline Hb value lower than 11 g/dL were
included in these analyses
aIncident ESA users with at least one ΔHb < 0 g/dL
bIncident ESA users with Hb values < 11 g/dL or with only one Hb value ≥11 g/
dL registered between the 2nd and the 6th month after ID
Table 3 Multivariate binary logistic regression to evaluate non
responsiveness to ESAs between the 2nd and the 6th month
after ID in CKD patients
Non responsiveness
ΔHb < 0 g/dL (at least once)
OR (95% CI) P-value
Baseline Hb (g/dL) 1.7 (1.2–2.2) < 0.001
Comorbidities
Hypertension 0.8 (0.3–1.7) 0.513
Concomitant drugs
Iron preparations 0.3 (0.2–0.7) 0.002
Folic acid 0.5 (0.2–1.1) 0.100
High dosage ACE inhibitors/ARBs 0.5 (0.3–0.9) 0.022
Laboratory Values
CRP 1.2 (1.0–1.5) 0.060
Transferrin saturation covariate was excluded because of the high proportion
of missing values (> 50%)
CKD ESA users starting the treatment at baseline Hb ≥ 11 g/dL were excluded
ACE angiotensin converting enzyme, CRP C-reactive protein
Table 4 Multivariate binary logistic regression to evaluate non
responsiveness to ESAs between the 2nd and the 6th month
after ID in cancer patients
Non responsiveness
ΔHb < 0 g/dL (at least once)
OR (95% CI) P-value
Baseline Hb (g/dL) 1.7 (1.1–2.4) 0.007
Comorbidities
Ischemic heart disease 2.7 (0.9–7.9) 0.072
Laboratory Values
Albumin (g/dL) 0.7 (0.5–1.1) 0.091
Potassium (mEq/L) 0.7 (0.4–1.0) 0.063
CRP (mg/dL) 1.1 (0.9–1.3) 0.537
Covariates as ferritin and vitamin B12 levels were excluded because of the high
proportion of missing values (> 40%)
Cancer ESA users starting the treatment at baseline Hb ≥ 11 g/dL
were excluded
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Fig. 3 ROC curve to predict the discriminant power of non-responsiveness in CKD
Fig. 4 ROC curve to predict the discriminant power of non-responsiveness in cancer
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saturation and ferritin levels, and ESA responsiveness. Find-
ing from the study highlighted that transferrin saturation,
but not ferritin, was statistically associated to ESA hypore-
sponsiveness [20]. On the hand, in our study, transferrin
saturation covariate was excluded from the analysis, due to
the high proportion of missing values (> 50%).
Minutolo et al. studied for the first time the risk of end-
stage renal disease in CKD patients, who were hypore-
sponsive to ESA treatment. The study findings demon-
strated that ESA hyporesponsiveness correlated to an
increased risk of end-stage renal disease and the authors
suggested that high ESA doses, together with the persist-
ence of anemia, could lead to hypoxia, tubular atrophy
and interstitial fibrosis, thus causing the progression of the
renal damage. On the other hand, no correlation between
the iron markers, CRP levels, serum parathyroid hormone,
body mass index and ESA response was found [14].
The influence of gender on ESA response is still contro-
versial. Female gender was associated with ESA hypore-
sponsiveness in our study cohort. This result is in line
with previous studies [19, 21], and may be related to the
underlying differences in iron release from reticuloendo-
thelial cells between the two genders [22]. Conversely,
other studies demonstrated that males were more likely to
be ESA hyporesponsive, in comparison to women [23, 24].
In our study, high doses of ACE inhibitor and/or ARBs
were related to ESA responsiveness. This data has been
controversially discussed in previous papers. Several studies
showing that ACE inhibitors and ARBs are associated to an
increase of ESA hyporesponsiveness [23, 25] hypothesized
that these anti-hypertensive drugs may interfere with
erythropoiesis. It is known that the activation of renin-
angiotensin system enhances the erythropoietin produc-
tions [26], while its inhibition due to ACE inhibitors may
exacerbate anaemia [27]. Moreover, it has been demon-
strated that ACE inhibitors may cause an increase in serum
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) levels,
which inhibit the recruitment of pluripotent erythroid cells
in bone marrow [28]. Other potential mechanisms by
which the considered anti-hypertensive drugs may cause
anemia are the serum reduction of specific cytokines, such
as interleukin-12, and/or of insulin-like growth factor-1,
which physiologically stimulate erythropoiesis [11].
Our results also demonstrated that ESA users with meta-
bolic acidosis (pH < 7.38 and serum HCO3− < 22mmol/l)
had a good ESA response. Due to the lack of evidence
explaining such potential association between metabolic
acidosis and ESA hyporesponsiveness, further investigations
on this potential predictive factor are needed.
Considering cancer patients, we found that higher base-
line Hb values were associated with ESA hyporesponsive-
ness (p-value = 0.007), together with the history of
ischemic heart disease, although this correlation is close to
be significant (p-value = 0.072). The role of cardiovascular
diseases as predictors of ESA hyporesponsiveness has been
previously studied [18, 29] in CKD patients and the most
liable mechanism is related to an increased production of
inflammatory cytokines, such as interleukins 1 and 6,
Tumor Necrosis Factor and interferon, which induce
apoptosis in erythroid progenitor cells and decrease the
iron availability by stimulating hepcidin production [30].
Further analyses are, on the other hand, required to con-
firm the role of cardiovascular diseases as predictors of
ESA hyporesponsiveness in cancer setting.
Strengths and limitations
This study has several strengths. Firstly, we may explore
data on ESA dispensing from two large Italian LHUs over a
7-year observation period. Secondly, thanks to the elec-
tronic therapeutic plans, information on the exact brand
name, number of dispensed packages, and indication for
use were available. Moreover, we could explore variations
in Hb values as a result of ESA treatment, using real-world
data from more than 1000 ESA users. Most of the previous
randomized clinical trials were conducted considering CKD
patients only, while our study explored the potential predic-
tors of ESA hyporesponsiveness in both CKD and cancer
patients. However, some limitations warrant caution. The
high frequency of missing values for some variables consid-
ered into the study (namely: transferrin saturation for CKD,
as well as ferritin and vitamin B12 for cancer) precluded
the possibility to test the independent effect of these risk
factors on the study outcome. Thus such an issue remains
to be investigated in a specifically designed future cohort
study. Furthermore, although we tested into the models a
series of laboratory risk factors assessed proximally to the
Hb measurement, the possibility of residual time dependent
confounding due to unmeasured confounders cannot be
excluded. Some ESA as well as concomitant drugs (i.e. iron
preparations) dispensing might not have been fully cap-
tured by the LHUs databases, as these drugs may be initially
dispensed directly by the public hospitals or purchased by
patients as out of pocket, thus not being traced using the
study data sources. However, it is unlikely that this limita-
tion affected the study results, as the potential selection bias
is expected to be minimal and non-differential between
ESAs responders and hyporesponders.
Finally, since the exact body weight of each ESA user
was not available and we could not evaluate the exact ESA
dosing regimen, we defined ESA hyporesponsiveness as a
decrease in Hb levels and, in the sensitivity analysis, as the
failure in achieving Hb values ≥11 g/dL, as reported by
Suttorp et al. in a multi-center, prospective study [7].
.
Conclusions
This study tries to identify some potential predictive fac-
tors associated with ESA hyporesponsiveness. Covariates
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as serum CRP or high levels of baseline Hb were con-
firmed to be associated with poor response to ESA. A
better knowledge of the factors associated with ESA re-
sponse may help avoiding the use of higher ESA doses,
and allow a better anaemia management in order to im-
prove the patients’ quality of life and reduce morbidity
and mortality of both CKD and cancer patients.
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